On 29 April 2025, our PhD candidate Tomás Alejandro Schmauck-Medina successfully defended his thesis “ATG-18/WIPI2, NAD+, and fasting converge through autophagy in healthy ageing and Alzheimer’s disease” for the degree of PhD (Philosophiae Doctor). Big congratulations to Dr. Schmauck-Medina.
We thank the mentoring team, especially to our senior researcher Dr. Sofie Lautrup for her excellent mentoring – Dr. Schmauck-Medina is officially the 1st PhD co-mentored by Dr. Sofie Lautrup.
The Year 2025 is approaching, and we would like to extend this opportunity to wish you and your beloved ones and very Merry Christmas and a Happy New Year 2025!
The Year of 2024 has been very productive and here we just list a few: 1. Postdoc Dr. Sifang Liao has received a postdoc grant from the prestigious CureAlzheimer´s Foundation to extend his study in the Fang and Nilsson laboratories (news in Karolinska); 2. Postdoc Dr. Queena Shu-qin Cao has secured a postdoc fellowship (3-year) from the highly competitive National Health Association; 3. Postdoc Dr. He-Ling Wang has secured a postdoc fellowship (3-year) from the highly competitive National Health Association; 4. Many of the Fang Lab team members have secured small grants from the UiO LifeScience Foundation (Johannes Frank/Sofie H. Lautrup, Alexander (Sasha) Anisimov, He-Ling Wang, and Beatriz Escobar Doncel); 5. He-Ling Wang defended her PhD and has set a high standard on the quality of a PhD from the Fang laboratory; 6. Thanks to Shu we had a very successful retreat in Poland (video); and 7. Many research papers and review papers are in preparation or under review and we anticipate a productive year 2025!
Here is a video of New Year 2025`wishes (video; and on-line)
On 20 Nov. 2024, our student He-Ling WANG successfully defended her PhD thesis entitled ‘Pharmacological and behavioural interventions to slow down Alzheimer’s disease: Focusing on mitochondrial quality control at molecular level’, mentored by Associate Prof. Evandro Fang, Prof. Geir Selbæk, and Dr. Janet Jian-Ying ZHANG.
Adjudication committee
First opponent: Chair Professor Guojun Bu, The Hong Kong University of Science and Technology, Second opponent: Centre Director Karen Duff, UK Dementia Research Institute, University College London, Third member and chair of the evaluation committee: Associate Professor Rune Enger, University of Oslo
Chair of the Defence
Professor Magnar Bjørås, University of Oslo
Summary
Alzheimer’s disease (AD) and related dementias present significant global health challenges, affecting over 57 million people worldwide. This thesis investigates mitochondrial dysfunction as a critical factor in AD progression, situated within n neuroscience and gerontology. The primary research questions focus on the impact of mitochondrial health on neuronal survival and the potential of therapeutic strategies to mitigate disease effects.
The research encompasses three interconnected projects: First, the evaluation of Spautin-1 as a therapeutic agent that enhances PINK1-PRKN-mediated mitophagy, promoting the removal of damaged mitochondria to improve neuronal function. Second, the assessment of NAD+ supplementation in the context of APOE4, a major genetic risk factor for AD, which improves mitochondrial metabolism and neuronal health. Third, the exploration of the synergistic effects of NAD+ supplementation combined with exercise on mitochondrial quality control and cognitive function in AD animal models characterized by amyloid-beta (Aβ) and Tau pathologies.
Key findings indicate that mitochondrial dysfunction contributes to neuronal loss and cognitive decline in AD. Spautin-1 enhances mitophagy and restores associative learning in affected models. Furthermore, NAD+ supplementation improves the metabolism of branched-chain amino acids (BCAAs), crucial for mitochondrial health, particularly in APOE4-associated AD. The combination of NAD+ supplementation with exercise further enhances mitochondrial function and neuronal resilience, highlighting a comprehensive strategy for AD management.
In conclusion, this thesis emphasizes the importance of mitochondrial management in slowing AD progression, suggesting that integrated therapeutic approaches may provide new avenues for effective treatment strategies.
Why is there such great variation in the health status of older people? Associate Professor Evandro Fei Fang leads a research collaboration to investigate this question.
Today’s older adults have much better health than previous generations. However, there are still major individual differences among older people of the same age: why can some people go hiking, while others need to use a wheelchair to get about? How can some play chess with their grandchildren, but others struggle to remember their own name?
Associate Professor Evandro Fei Fang, together with his collaborators, has been awarded a multi-million dollar contract from Wellcome Leap’s Dynamic Resilience program, jointly funded with Temasek Trust, to explore why there are such large differences in the health status of older people.
“I am excited to lead this project. As a researcher on aging for more than 10 years, a key question is always why some people age so well, while many others suffer from physical decline and memory loss”, says Fang.
Is it possible to reduce the risk of delirium?
The research will focus on delirium, an acute state of mental confusion that is very common among people over 70 who are hospitalized for infection, injury or surgery, and which can lead to frailty progression and/or dementia.
“Delirium received significant attention during the pandemic, as many older patients who were hospitalized with Covid-19 developed delirium,” Fang explains, continuing:
“In this project, our goal is to understand at the very fundamental level of molecules and cells why some older adults are more at risk of delirium than others and whether it might be possible to reduce that risk, by increasing their resilience”.
Combining clinical knowledge with laboratory methods and AI
“This major funding, awarded competitively through the global ‘Dynamic Resilience’ program, gives us opportunities to explore this question both in the laboratory and in the clinic”, Fang says.
The researchers aim to study the long-running human HUNT cohorts combined with lab-based experiments and use the power of artificial intelligence (AI).
When combined, they can help Fang and collaborators to measure, predict and potentially improve dynamic resilience, the ability to recover fully from acute stressors such as major infection or injury, particularly in delirium and dementia.
He adds: “If we are successful, this project could have immediate clinical applications.”
The project includes experts in aging, delirium and dementia
Partners in the project include Professor Leiv Otto Watne at UiO and Akershus University Hospital and Professor Geir Selbæk at UiO and the Norwegian National Centre for Ageing and Health, who are national experts in delirium and dementia respectively.
The project also includes British partners, with Professor David C. Rubinsztein at the University of Cambridge, Professor Guang Yang at Imperial College London, and MindRank Technologies Limited, a company working on artificial intelligence (AI).
Evandro Fei Fang’s research group. Photo: He-Ling Wang.
An important and prioritized research topic
“Congratulations are in order! Aging is an important and prioritized research topic, and we are grateful that Evandro Fei Fang, Leiv Otto Watne and Geir Selbæk, along with their collaborators, have received this significant and competitive funding. This also opens the door to new sources of funding for our researchers”, Dean of Research Jan Bjaalie, says.
On 30 Nov. 2023, Alice Rui-xue AI received her doctoral degree certificate from the vice rector of the University of Oslo (UiO), Norway. What an important moment for Dr. AI and the Fang lab. Big congratulations.
Big congratulations to the Evandro Fang lab postdoc Dr. Jun-ping Pan in securing a prestigious 3-year postdoc fellowship from the Nasjonalforeningen for folkehelsen (The National Association for Public Health), Norway. In this project, Dr. Pan will be investigating novel molecular mechanisms that lead to compromised garbage clearance in old age, especially in patients suffering with Alzheimer’s disease. He will be using animal models combined with human sampels to address the questions.
About Jun-ping Pan Junping obtained his Master’s degree from the Neuropharmacology Department of Jinan University under the supervision of Professor Huan-min Luo in 2018. He is mainly engaged in research on how methyl 3,4-dihydroxybenzoate induces neural stem cells to differentiate into cholinergic neurons in vitro. Junping worked in the Neurosurgery Department of Guangdong Women and Children’s Medical Center in 2019. He received doctoral degree in immunology from the School of Basic Medical Sciences, Jinan University under the supervision of Professor Guobing Chen and Evandro F. Fang in 2022. His PhD project was focused on ULK1 abrogation of memory loss and pathologies in 5XFAD and hTau.P301S murine models of Alzheimer’s disease. In his postdoc programme, he is continuing to study the mechanics of ULK1 in AD and the role of ULK1 in healthy aging. He is also studying the role of traditional Chinese medicine in inducing mitophagy to improve AD. His hobbies are hiking, boxing, swimming, and gourmet cooking.
Utdeling av Nasjonalforeningen for folkehelsens forskningspriser ved H.M. Kong Harald. F.v Prisvinnere Evandoro Fei Fang og Dan Atar. The king together with the laureates of this year’s research awards: Dan Atar (middle) for research on cardiovascular disease and Evandro Fei Fang (left) for research on dementia. Photo: Nasjonalforeningen for folkehelsen
Evandro Fang and Mina Gerhardsen (general secretariat of the National Association for Public Health) are in front of the gift of the award, an art of ageing. Photo: Nasjonalforeningen for folkehelsen
On April 18 2023, researcher Evandro Fei Fang at the University of Oslo and Akershus University Hospital is the winner of the National Association for Public Health’s Dementia Research Prize for 2023.
His work in the search for effective drugs against Alzheimer’s disease is described as “groundbreaking”.
At the same time, Fang reminds that all good forces must make a joint effort to fight the disease that affects many of us.
Network for knowledge exchange Over the past five years, Evandro Fei Fang has contributed to establishing networks for knowledge exchange between dementia researchers, held lectures about the research and his findings at prestigious universities worldwide and put the fight against dementia on the map and agenda in a number of ways.
The main reason for the award is also a concrete solution proposal Fang and his research team have put forward regarding a mechanism for removing damaged mitochondria in the brain. This track is referred to by several as “groundbreaking” in the search for effective medication against Alzheimer’s disease.
Garbage in the brain – We believe that a main reason why we experience memory loss and other cognitive impairments when we get older is that a lot of “rubbish” accumulates in our brains over time. There is a “garbage truck” (termed “autophagy” in biology) in the brain that normally clears this away when we are younger, he says.
– When we age, however, this “garbage truck” becomes less efficient. The question is, why does this function lose effectiveness? There are several reasons, but an important element is that the garbage truck’s “engine” (termed “mitochondria” in biology) begins to wear out after many years of work. And if the engine goes on strike, the garbage truck doesn’t work well.
From theory to dementia drugs? His hypothesis about what goes wrong when the form of dementia develops is also far more than an exciting theory. The mechanism has been replicated in studies carried out by several other research teams in a number of countries, which strengthens the belief in the potential medicinal value.
This understanding of Alzheimer’s has also led to Fang and his research team identifying two promising components which they hope can be further developed into effective medicines against the disease.
Evandro Fei Fang emphasizes the belief that this track can eventually lead to a better everyday life for those of us affected by Alzheimer’s.
– We should concentrate on repairing the garbage truck’s engine. The reason why we have different forms of plaque in the brain, and thus defining features of the disease picture in an Alzheimer’s diagnosis, is because this rubbish is created, but not removed. We need to add energy that restarts the engine and gets this cleaning process in the brain going again, says the award winner.
Cure requires community-wide dedication At the same time, for Evandro Fei Fang, the fight against dementia is something that cannot be won on one’s own. He wants a joint boost against the disease, and believes we all play a key role on the road to a better future for people with dementia and their relatives.
– Our understanding of dementia and how we find the way to an effective drug against Alzheimer’s does not rest only on one lab or one research team. The whole society must work towards the same goal, not least in terms of funding. Our financial contributors, the ability to collaborate, the infrastructure around research and support from politicians and decision-makers are all very important elements. We must all play as a team if we are to manage this, he emphasizes.
The researcher is also clear about how much it means that ordinary Norwegians are on the team.
– Every kroner we receive in support moves us a small step towards the big goal. The support from private individuals through the National Association for Public Health is therefore very important to those of us who work with this every day. I hope and believe that what we are working on will be able to give a great deal of value back to society in the form of better prevention and better treatment of Alzheimer’s disease. My big thanks go to everyone who donates to the cause, says Evandro Fei Fang emphatically.
The jury’s reasoning Since 2 October 2017, Evandro Fei Fang has been employed as a researcher at UiO, where he has established a very active group and conducts research on ageing and dementia at an internationally high level.
Fang and his colleagues have put forward a new etiological hypothesis for Alzheimer’s disease – defective mitophagy, the mechanism for removing damaged mitochondria (damaged engine of the garbage truck), the cells’ energy supply.
This hypothesis has been very well received in the competitive Alzheimer’s field with 676 citations to his 2017 article in Nature Neuroscience as of April this year.
The proposed mechanism is supported by trials in many species and welcomed in the international trade press (among others Kingwell 2019 Nat Rev Drug Discov) and international media. An editorial in Nat Rev Drug Discov points out that increasing mitophagy is a new and promising strategy for the treatment and prevention of Alzheimer’s disease.
The studies provide immediate clinical translation, since Fang has characterized several mitophagy-induced substances, e.g. the NAD+ precursor nicotinamide riboside (NR), and the naturally occurring urolithin (UA), as potential drugs against Alzheimer’s, and is now participating in clinical testing of NR in Alzheimer patients.
Very recently, the Fang laboratory has made an important new discovery: they used artificial intelligence with wet-lab validation in AD animals, and have identified two mitophagy-inducing ‘lead compounds’ as robust anti-AD drug candidates.
Since 2003, over 250 drugs have been in clinical testing for Alzheimer’s, but almost all have failed. The substances have mostly only been aimed at eliminating Aβ plaques and Tau tangles. It therefore seems necessary to focus on other mechanisms.
Fang and colleagues have proposed that impaired function of the NAD+-mitophagy axis is a ‘new’ etiological mechanism for AD. Fang has shown that NAD+ treatment increases mitophagy and counteracts memory loss in 4 animal models of Alzheimer’s. This has high clinical relevance, in the short and long term: Nicotinamide riboside (NA), which is converted to NAD+ in the body, is absorbed easily after oral administration without known toxicity. Clinical trials of NR on AD patients are in progress.
In Chinese 挪威国王哈拉尔五世(Harald V av Norge)向方飞(Evandro Fei Fang)副教授颁发挪威国家公共卫生协会痴呆症研究奖
While the Fang lab was opened on the 2nd Oct 2017, this week we are celebrating the 5th year anniversary of the Fang lab at the Universtiy of Oslo (UiO) and the Akershus University Hospital (Ahus), Norway.
Some bulleted summary 1. We have 25 young students trained by the Fang lab and are now in their new chapters of career development (https://evandrofanglab.com/alumni/). 2. Two postdocs have secured good positions: Yahyah Aman, Ph.D. (King´s College London), Postdoc Fellow (2018.02-2021.01); Current position: Researcher at UCL, UK; currently Associate editor at Nature Ageing. Chenglong Xie, Ph.D. (Shanghai Jiaotong U.), Postdoc Fellow (2019.09-2020.11); Current position: Faculty at Wenzhou Medical University, China. 3. Over 55 papers published in the last 5 years, including papers in Nature Neuroscience (2019), Cell Metabolism (2019, postdoc and then researcher Dr. Sofie Lautrup as first author), Nature Ageing (2021, Postdoc Dr. Yahyah Aman and DPhil student Tomas Schmauck-Medina as co-first authors), and Nature Biomedical Engineering (2022, Postdoc Chenglong Xie and student Alice Rui-xue Ai as co-first authors). https://evandrofanglab.com/publications/ 4. We have been in the news in VG among others https://evandrofanglab.com/news-and-events/ 5. As a member in a joint EU grant on the study of NAD in healthy ageing: https://lnkd.in/driikYM9 6. In the toughest funding period (around 5% in the renewal category): https://lnkd.in/dpnVzXXR 7. Our AI-based identification of mitophagy inducers as drug candidates of Alzheimer’s disease: https://lnkd.in/eD5rWbU9
Greetings from the Fang lab current members : video (you can not miss it)